Implications for research
Continued collection of data on specific parameters of thrombosis and
haemostasis from pregnant women affected by COVID-19 is necessary to
further elucidate the incidence, prognostic value, and implications of
coagulopathy, and thromboembolism in pregnancy.
More detailed investigation of coagulation abnormalities may also be
useful. These could include studies such as specialised factor assays
(taking into account the normal haemostatic changes that occur in
pregnancy).
Determination of specific cut-off values of aberrant haemostatic
parameters associated with adverse outcomes in pregnancy is needed.
Given the rarity of the condition, even in the face of a global
pandemic, and in absence of systematic studies or until data from
randomised control trials become available, international registries can
be of immense value in achieving this aim. The International Society on
Thrombosis and Haemostasis has developed the Pregnancy and
COVID-19-Associated Coagulopathy (COV-PREG-COAG) Registry, precisely to
fulfil this aim. Participation in the Registry is open to health care
providers worldwide and can be accessed at:
https://redcap.isth.org/surveys/?s=4JPX9W98RH.